CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy

Behrouz Shademan ¹ , Vahidreza Karamad ¹, Alireza Nourazarian ², Cigir Biray Avcı ¹ *

Cited by CrossRef: 4

1- Mohaghegh N, Ahari A, Zehtabi F, Buttles C, Davani S, Hoang H, Tseng K, Zamanian B, Khosravi S, Daniali A, Kouchehbaghi N, Thomas I, Serati Nouri H, Khorsandi D, Abbasgholizadeh R, Akbari M, Patil R, Kang H, Jucaud V, Khademhosseini A, Hassani Najafabadi A. Injectable hydrogels for personalized cancer immunotherapies. Acta Biomaterialia. 2023;172:67 [Crossref]

2- Kim M, Kang H, Baek J, Cho M, Chung E, Kim S, Chung J, Chun K. Disrupting Notch signaling related HES1 in myeloid cells reinvigorates antitumor T cell responses. Exp Hematol Oncol. 2024;13(1) [Crossref]

3- Shademan B, Masjedi S, Karamad V, Isazadeh A, Sogutlu F, rad M, Nourazarian A. CRISPR Technology in Cancer Diagnosis and Treatment: Opportunities and Challenges. Biochem Genet. 2022;60(5):1446 [Crossref]

4- Amiri M, Moaveni A, Majidi Zolbin M, Shademan B, Nourazarian A. Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9. Front Immunol. 2024;15 [Crossref]

5- Liu G, Ji Y. Electrochemiluminescent evaluation of GLUT4 expression in rat adipocytes induced by Ganoderma lucidum polysaccharides. International Journal of Biological Macromolecules. 2024;270:132106 [Crossref]